// App-Quantinova.ai

: Effect of Dapagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, on Vascular Function in Patients with Type 2 Diabetes Compared with Gliclazide

Researchers

Presenter

  • SOO LIM

Principal Investigators

  • N/A

Medical Centers

  • N/A

Locations

  • Canada

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Endocrine/metabolic Diseases (ME)

  • Cardiovascular (CVS)

Disease

  • Type 2 diabetes mellitus

  • Dyslipidemia

  • Diabetes

Biomarkers

  • Hemoglobin A1c

  • Apoptotic body index

Drug/Treatment

  • Dapagliflozin

  • Adianor

  • Metformin Hydrochloride

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved